Administer by deep subcutaneous injection, preferably into the abdominal wall or anterior/posterior lateral thigh. Alternate injection sites. Do not inject intramuscularly. Do not rub the injection site after administration.

Enoxaparin potentiates the inhibitory effect of antithrombin III on Factor Xa and, to a lesser extent, Factor IIa (thrombin). This selective inhibition prevents the formation and growth of blood clots.

• •Active major bleeding or conditions associated with a high risk of uncontrolled bleeding (e.g., active gastric ulcer, hemorrhagic stroke).
• •History of heparin-induced thrombocytopenia (HIT) with or without thrombosis.
• •Hypersensitivity to enoxaparin, heparin, or pork products.
• •Spinal/epidural anesthesia or lumbar puncture within 24 hours of enoxaparin administration (for prophylactic doses).

Store below 25°C (77°F), do not freeze. Protect from light. Keep out of reach of children.

Accidental overdose may lead to hemorrhagic complications. The anticoagulant effects can be largely neutralized by the slow intravenous injection of protamine sulfate. The dose of protamine sulfate should be carefully calculated based on the administered enoxaparin dose and time since administration.

Pregnancy Category B. Use during pregnancy only if clearly needed and potential benefits outweigh risks. Enoxaparin does not cross the placental barrier. Minimal excretion into breast milk; considered compatible with breastfeeding with caution.